STAT Plus BristolMyers Squibb racing to convince shareholders to back its planned $74 billion acquisition of Celgene could have its plans derailed by a pair of hugely influential financial advisers. httpsbuff.ly2ILT6OtÂ

STAT Plus: Bristol-Myers Squibb, racing to convince shareholders to back its planned $74 billion acquisition of Celgene, could have its plans derailed by a pair of hugely influential financial advisers. https://buff.ly/2ILT6Ot

10:00 EST 3 Mar 2019 | STAT

STAT Plus: Bristol-Myers Squibb, racing to convince shareholders to back its planned $74 billion acquisition of Celgene, could have its plans derailed by a pair of hugely influential financial advisers. https://buff.ly/2ILT6Ot

More From BioPortfolio on "STAT Plus: Bristol-Myers Squibb, racing to convince shareholders to back its planned $74 billion acquisition of Celgene, could have its plans derailed by a pair of hugely influential financial advisers. https://buff.ly/2ILT6Ot "